# Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

> **NCT07415135** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhu Yinjie** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery
- **DRUG:** 0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery
- **DRUG:** 0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery

## Key facts

- **NCT ID:** NCT07415135
- **Lead sponsor:** Zhu Yinjie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07415135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07415135, "Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07415135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*